Common Contracts
6 similar Executive Employment Agreement contracts by Ovid Therapeutics Inc.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 16th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Jeff Rona (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Business Officer pursuant to the terms of an Executive Employment Agreement with the Company effective September 30, 2020 (the “Prior Agreement”). Executive and the Company hereby agree to this amended agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of June 2, 2021 (the “Effective Date”) and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain bolded terms used in this Agreement are defined in Section 6.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 30th day of September, 2020, between Jeff Rona (“Executive”) and OVID THERAPEUTICS INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 6.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Thomas Perone (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its General Counsel, Corporate Secretary and Chief Compliance Officer pursuant to the terms of an Executive Employment Agreement with the Company effective March 11, 2019 (the “Prior Agreement”). Executive and the Company hereby agree to this amended agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of January 1, 2020 (the “Effective Date”) and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain bolded terms used in this Agreement are defined in Section 6.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 15th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 21st day of October, 2019, between Jason Tardio (“Executive”) and OVID THERAPEUTICS INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 6.
THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 11th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Tim Daly (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Executive Vice President, Finance, Corporate Controller and Treasurer pursuant to the terms of an Employment Agreement dated August 17th, 2015, as amended and restated on May 5, 2017, and as amended and restated on November 1, 2019 (the “Prior Agreements”). Executive and the Company hereby agree to this amended agreement. The terms and conditions set forth in this THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of December 18, 2019 (the “Effective Date”) and shall supersede and replace the terms and conditions set forth in the Prior Agreements. Certain bolded terms used in this Agreement are defined in Section 6.
SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 11th, 2020 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Amit Rakhit (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Medical and Portfolio Management Officer pursuant to the terms of an Amended and Restated Executive Employment Agreement with the Company effective May 4, 2017 (the “Prior Agreement”). Executive and the Company hereby agree to this second amended agreement for Executive’s promotion to President and Chief Medical Officer. The terms and conditions set forth in this SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of November 1, 2019 (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in all prior agreements with the Executive, including, without limitation, the Prior Agreement. Certain bolded terms used in this Agreement are defined in Section 6.
